
Early-stage B2B venture capital firm backed by experienced enterprise operators who invest alongside it

A venture capital firm investing in life sciences companies through multiple funds

Bay City Capital is a venture capital firm focused on investing in life sciences. The firm has raised five venture capital funds and says it has invested in more than 100 companies worldwide. Portfolio companies and partners mentioned on its site include Dermira, which received FDA Fast Track designation for a treatment; Synchronicity, working on a glioblastoma treatment; and Nevro, which received FDA approval for a spinal cord stimulation device. Its site also references MGL-3196 achieving liver biopsy endpoints in NASH patients, and diagnostics company Accriva, which was acquired by Werfen. The firm has announced a new fund together with GF Xinde, launched a company called Bridge Medicines with partners, and noted Cydan's announcement of Vtesse's acquisition by Sucampo among its portfolio developments.
Summary written by TrustList from the business's own published information, Sep 2026.
2 images - click to enlarge
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about Bay City Capital.
Similar listings buyers compare against this one.

Early-stage B2B venture capital firm backed by experienced enterprise operators who invest alongside it

Member-based investor group funding early-stage companies through monthly review and a chapter roadshow

Venture capital firm partnering with founders from first idea through to public listing

Decentralised bandwidth network on which developers build and users run censorship-resistant VPN applications

A publicly listed venture capital fund investing in growth-stage European fintech companies

Venture capital firm backing early stage technology companies in the American Midwest
Everything here links back to the same verified catalogue. Pick your next stop.